KR101870056B1 - 유전자 요법 벡터와 시토신 디아미나아제 - Google Patents

유전자 요법 벡터와 시토신 디아미나아제 Download PDF

Info

Publication number
KR101870056B1
KR101870056B1 KR1020167016947A KR20167016947A KR101870056B1 KR 101870056 B1 KR101870056 B1 KR 101870056B1 KR 1020167016947 A KR1020167016947 A KR 1020167016947A KR 20167016947 A KR20167016947 A KR 20167016947A KR 101870056 B1 KR101870056 B1 KR 101870056B1
Authority
KR
South Korea
Prior art keywords
gly
leu
val
glu
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167016947A
Other languages
English (en)
Korean (ko)
Other versions
KR20160079149A (ko
Inventor
해리 이. 그루베르
더글라스 졸리
오마르 페레즈
크리스토퍼 알. 로그
Original Assignee
토카겐 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토카겐 인크. filed Critical 토카겐 인크.
Publication of KR20160079149A publication Critical patent/KR20160079149A/ko
Application granted granted Critical
Publication of KR101870056B1 publication Critical patent/KR101870056B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167016947A 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제 Expired - Fee Related KR101870056B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10066608P 2008-09-26 2008-09-26
US61/100,666 2008-09-26
US12061808P 2008-12-08 2008-12-08
US61/120,618 2008-12-08
US18682309P 2009-06-13 2009-06-13
US61/186,823 2009-06-13
PCT/US2009/058510 WO2010045002A2 (en) 2008-09-26 2009-09-26 Gene therapy vectors and cytosine deaminases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117008744A Division KR101724162B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016894A Division KR102025502B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제

Publications (2)

Publication Number Publication Date
KR20160079149A KR20160079149A (ko) 2016-07-05
KR101870056B1 true KR101870056B1 (ko) 2018-07-23

Family

ID=42060421

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167016947A Expired - Fee Related KR101870056B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제
KR1020187016894A Expired - Fee Related KR102025502B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제
KR1020117008744A Expired - Fee Related KR101724162B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187016894A Expired - Fee Related KR102025502B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제
KR1020117008744A Expired - Fee Related KR101724162B1 (ko) 2008-09-26 2009-09-26 유전자 요법 벡터와 시토신 디아미나아제

Country Status (18)

Country Link
US (3) US8722867B2 (https=)
EP (4) EP2346995B1 (https=)
JP (6) JP5684130B2 (https=)
KR (3) KR101870056B1 (https=)
CN (4) CN102227503B (https=)
AU (1) AU2009303690B2 (https=)
BR (1) BRPI0919113A2 (https=)
CA (1) CA2738472A1 (https=)
CO (1) CO6362050A2 (https=)
DK (1) DK2346995T3 (https=)
EA (2) EA201790824A3 (https=)
ES (2) ES2706899T3 (https=)
IL (3) IL211847A (https=)
MX (3) MX2011003039A (https=)
MY (1) MY156333A (https=)
NZ (1) NZ592070A (https=)
WO (2) WO2010045002A2 (https=)
ZA (1) ZA201102115B (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386646B1 (en) 1998-10-01 2016-12-21 University Of Southern California Gene delivery system and methods of use
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
CN102227503B (zh) * 2008-09-26 2015-10-21 托卡根公司 重组载体
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
JP5923037B2 (ja) 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
EP2913402B1 (en) 2010-07-16 2017-10-18 Tocagen Inc. Retrovirus detection
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
US20140178854A1 (en) 2010-10-31 2014-06-26 Tocagen Inc. Antisera assays for mlv related viruses in humans and other mammals
CN107488233A (zh) * 2011-06-02 2017-12-19 台北荣民总医院 治疗感染性与恶性疾病的标靶化学治疗药物的形成方法
KR101554678B1 (ko) * 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
HK1213923A1 (zh) * 2012-11-15 2016-07-15 Esperance Pharmaceuticals, Inc. 促卵激素(fsh)/胞溶域融合構造體和其製備及使用方法
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
ES2745103T3 (es) 2013-06-15 2020-02-27 Tocagen Inc Partículas inmunosupresivas similares a virus basadas en gammaretrovirus
WO2015021077A1 (en) * 2013-08-05 2015-02-12 Tocagen Inc. Recombinant vector with optimized a-bulge
CN103966260A (zh) * 2014-03-07 2014-08-06 山东农业大学 一种基于J亚群禽白血病病毒pol基因保守序列的siRNA重组干扰载体及其制备方法和应用
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
WO2015168102A2 (en) * 2014-04-28 2015-11-05 Board Of Regents, The University Of Texas System Prolonged protein stabilization by resveratrol
CN104557602B (zh) * 2015-01-07 2016-08-17 华东师范大学 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
JP2018526007A (ja) 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
GB2572716B (en) 2016-11-29 2022-06-22 Articure Co Ltd Gene Therapy Vector System and Prodrug Genes
CN107058314B (zh) * 2016-11-30 2020-09-04 暨南大学 一种启动子及其应用
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020530979A (ja) 2017-06-30 2020-11-05 インスクリプタ， インコーポレイテッド 自動細胞処理方法、モジュール、機器及びシステム
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR20200036873A (ko) * 2017-07-14 2020-04-07 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
KR20200104371A (ko) 2017-12-27 2020-09-03 에티컨, 엘엘씨 광 결핍 환경에서의 형광 이미징
EP3758755A1 (en) * 2018-02-26 2021-01-06 Ablynx N.V. Improved nucleotide sequences encoding peptide linkers
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
CN110396504A (zh) * 2018-04-25 2019-11-01 江苏省原子医学研究所 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途
CA3108767A1 (en) 2018-06-30 2020-01-02 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11096565B2 (en) 2019-06-20 2021-08-24 Cilag Gmbh International Driving light emissions according to a jitter specification in a hyperspectral, fluorescence, and laser mapping imaging system
US10952619B2 (en) 2019-06-20 2021-03-23 Ethicon Llc Hyperspectral and fluorescence imaging and topology laser mapping with minimal area monolithic image sensor
US11266304B2 (en) 2019-06-20 2022-03-08 Cilag Gmbh International Minimizing image sensor input/output in a pulsed hyperspectral imaging system
US12440085B2 (en) 2019-06-20 2025-10-14 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed laser mapping imaging system
US11516387B2 (en) 2019-06-20 2022-11-29 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US11389066B2 (en) 2019-06-20 2022-07-19 Cilag Gmbh International Noise aware edge enhancement in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US11311183B2 (en) 2019-06-20 2022-04-26 Cilag Gmbh International Controlling integral energy of a laser pulse in a fluorescence imaging system
US12013496B2 (en) 2019-06-20 2024-06-18 Cilag Gmbh International Noise aware edge enhancement in a pulsed laser mapping imaging system
US11944273B2 (en) 2019-06-20 2024-04-02 Cilag Gmbh International Fluorescence videostroboscopy of vocal cords
US11012599B2 (en) 2019-06-20 2021-05-18 Ethicon Llc Hyperspectral imaging in a light deficient environment
US11589819B2 (en) 2019-06-20 2023-02-28 Cilag Gmbh International Offset illumination of a scene using multiple emitters in a laser mapping imaging system
US11237270B2 (en) 2019-06-20 2022-02-01 Cilag Gmbh International Hyperspectral, fluorescence, and laser mapping imaging with fixed pattern noise cancellation
US11617541B2 (en) 2019-06-20 2023-04-04 Cilag Gmbh International Optical fiber waveguide in an endoscopic system for fluorescence imaging
US12126887B2 (en) 2019-06-20 2024-10-22 Cilag Gmbh International Hyperspectral and fluorescence imaging with topology laser scanning in a light deficient environment
US11280737B2 (en) 2019-06-20 2022-03-22 Cilag Gmbh International Super resolution and color motion artifact correction in a pulsed fluorescence imaging system
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
AU2020407048A1 (en) 2019-12-18 2022-06-09 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US11225674B2 (en) 2020-01-27 2022-01-18 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN111944810B (zh) * 2020-07-29 2022-05-27 中国农业大学 靶向敲除TNFα基因的sgRNA和敲除TNFα基因的猪胚胎成纤维细胞系及其应用
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
EP4274890A4 (en) 2021-01-07 2024-11-27 Inscripta, Inc. MAD-NUCLEASES
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating diseases and disorders driven by eosinophils
CN118697758B (zh) * 2024-05-31 2025-10-21 河北大学 miR-128-1-5p的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
AU680508B2 (en) 1993-04-06 1997-07-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Gibbon ape leukemia virus-based retroviral vectors
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
EP0728195A1 (en) 1993-10-12 1996-08-28 Chiron Corporation Methods for preserving recombinant viruses
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
ATE412740T1 (de) 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
JP2001504325A (ja) 1996-09-27 2001-04-03 マキシジェン，インコーポレイテッド 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
JP2001505060A (ja) 1997-01-14 2001-04-17 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子受容体 ５
KR100570935B1 (ko) 1997-01-17 2006-04-13 맥시겐, 인크. 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
ATE418608T1 (de) 1997-03-18 2009-01-15 Novozymes As Methode zur herstellung einer bibliothek mittels dna-shuffling
WO1998041653A1 (en) 1997-03-18 1998-09-24 Novo Nordisk A/S An in vitro method for construction of a dna library
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
CA2292790A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999020742A2 (en) 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc MODIFICATION OF VIRUSTROPISMIUS AND THE ECONOMIC SPECTRUM BY VIRAL GENOM MIXING
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
AU3291099A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
EP1054973A1 (en) 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
WO1999060110A2 (en) 1998-05-20 1999-11-25 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
IL140100A0 (en) 1998-06-29 2002-02-10 Phylos Inc Methods of generating highly diverse libraries
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
IL140441A0 (en) 1998-09-29 2002-02-10 Maxygen Inc Shuffling of codon altered genes
EP2386646B1 (en) * 1998-10-01 2016-12-21 University Of Southern California Gene delivery system and methods of use
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
EP1151409A1 (en) 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
EP1173597A1 (en) 1999-04-29 2002-01-23 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
WO2001004266A1 (en) 1999-07-08 2001-01-18 The Regents Of The Universty Of California A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001241939A1 (en) 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
US20030003565A1 (en) * 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
JP4344858B2 (ja) * 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
IL165984A0 (en) 2002-07-17 2006-01-15 Bristol Myers Squibb Co Transgenic non-huammal cells isolated therefrom and an isolated nucleic acid construct
EP1534847B1 (en) * 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
JP4672659B2 (ja) 2003-07-21 2011-04-20 トランジェーヌ、ソシエテ、アノニム 改善されたシトシンデアミナーゼ活性を有するポリペプチド
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
WO2006048749A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
WO2006058231A2 (en) * 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US7968698B2 (en) 2005-05-25 2011-06-28 The Regents Of The University Of California Optimized core promoters and uses thereof
US20070048285A1 (en) * 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
US20090028842A1 (en) * 2005-09-30 2009-01-29 Zgene A/S Dekkera/Brettanomyces Cytosine Deaminases And Their Use
AU2006297112B2 (en) * 2005-10-01 2013-04-18 Charles Stout Regulatable fusion promoters
US8034355B2 (en) 2005-10-07 2011-10-11 Presidents And Fellows Of Harvard College Attenuated nonsegmented negative-sense RNA viruses with reduced mRNA cap methyltransferase activity comprising mutations within conserved domain VI of the large polymerase
EP1795596A1 (en) * 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
EP2004677A2 (en) 2006-03-17 2008-12-24 Aarhus Universitet Chimeric viral envelopes
WO2007123737A2 (en) * 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US8329162B2 (en) * 2006-07-21 2012-12-11 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102227503B (zh) * 2008-09-26 2015-10-21 托卡根公司 重组载体
JP5923037B2 (ja) * 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
BR112013003135A2 (pt) 2010-08-13 2017-11-07 Pioneer Hi Bred Int polinucletídeo e polipeptídeo isolado ou recombinante, construto de ácido nucleico, célula, planta, explante vegetal, semente transgênica, método para produção de célula vegetal para controle de plantas daninhas e para detecção de um polipeptídeo hppd e um polinucleotídeo.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession Number 1YSB_A (2007.10.01.)

Also Published As

Publication number Publication date
IL248833A0 (en) 2017-01-31
IL248833B (en) 2019-01-31
MY156333A (en) 2016-02-15
JP6062485B2 (ja) 2017-01-18
CN102227503B (zh) 2015-10-21
CO6362050A2 (es) 2012-01-20
KR101724162B1 (ko) 2017-04-07
JP5992548B2 (ja) 2016-09-14
CN105274125A (zh) 2016-01-27
KR20110063673A (ko) 2011-06-13
EP3460061A1 (en) 2019-03-27
CN105624193B (zh) 2021-07-13
CN105624193A (zh) 2016-06-01
IL264214A (en) 2019-02-28
AU2009303690B2 (en) 2014-06-19
JP2015186479A (ja) 2015-10-29
EA201790824A3 (ru) 2017-12-29
JP2019141088A (ja) 2019-08-29
KR102025502B1 (ko) 2019-09-25
KR20180069131A (ko) 2018-06-22
IL211847A0 (en) 2011-06-30
EP2344648A4 (en) 2012-03-14
NZ592070A (en) 2012-07-27
EP3502256A3 (en) 2019-09-25
CN102227501B (zh) 2016-11-16
DK2346995T3 (en) 2019-02-11
CN102227501A (zh) 2011-10-26
BRPI0919113A2 (pt) 2016-08-09
EP2346995A4 (en) 2011-12-07
KR20160079149A (ko) 2016-07-05
JP2012503986A (ja) 2012-02-16
MX2011003039A (es) 2011-08-15
JP2015119712A (ja) 2015-07-02
EP2344648B1 (en) 2018-11-14
EA027693B1 (ru) 2017-08-31
MX2018008440A (es) 2021-06-15
US20140242033A1 (en) 2014-08-28
JP2012503987A (ja) 2012-02-16
US8722867B2 (en) 2014-05-13
JP5684130B2 (ja) 2015-03-11
CA2738472A1 (en) 2010-04-22
IL211847A (en) 2016-11-30
US10035983B2 (en) 2018-07-31
WO2010036986A2 (en) 2010-04-01
WO2010045002A3 (en) 2010-08-26
JP5771147B2 (ja) 2015-08-26
MX357418B (es) 2018-07-09
EP2346995A2 (en) 2011-07-27
CN102227503A (zh) 2011-10-26
EA201790824A2 (ru) 2017-08-31
EP3502256A2 (en) 2019-06-26
JP6523224B2 (ja) 2019-05-29
WO2010036986A3 (en) 2010-07-01
AU2009303690A1 (en) 2010-04-22
ES2709481T3 (es) 2019-04-16
EP2344648A2 (en) 2011-07-20
ES2706899T3 (es) 2019-04-01
EA201170492A1 (ru) 2011-10-31
ZA201102115B (en) 2012-07-25
IL264214B (en) 2020-01-30
JP2017018121A (ja) 2017-01-26
US20190185821A1 (en) 2019-06-20
WO2010045002A2 (en) 2010-04-22
EP2346995B1 (en) 2018-11-07
US20110217267A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
KR101870056B1 (ko) 유전자 요법 벡터와 시토신 디아미나아제
DK2443242T3 (en) Production cells for replicative retroviral vectors
JP7721589B2 (ja) 細胞の遺伝子修飾のための非組込みｄｎａベクター
AU2014356427B2 (en) Stable episomes based on non-integrative lentiviral vectors
AU699706B2 (en) Improved vectors for gene therapy
US6027722A (en) Vectors for gene transfer
AU2016317936A1 (en) Recombinant vectors comprising 2A peptide
US20120128631A1 (en) Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
CN111593073A (zh) 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒
US11129890B1 (en) Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
CA3041673A1 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
KR102584628B1 (ko) T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
CA2803011C (en) Retrovirus detection
US20210010031A1 (en) Lentiviral vectors for high-titer transduction of primary human cells
TW202302857A (zh) 多臂黏液瘤(myxoma)病毒
AU782255B2 (en) Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy
CA2445078A1 (fr) Plasmide chimere comprenant un genome retroviral replicatif et utilisations
WO2000017376A1 (en) Replication deficient retroviral vector system and methods of using
HK1240620A1 (en) Producer cells for replication competent retroviral vectors
CN110699381A (zh) 地中海贫血病基因治疗载体构建方法及其用途
HK40061400A (en) Recombinant vectors comprising genes for binding domains and secretable peptides
CN113677800A (zh) 包含用于结合结构域和可分泌肽的基因的重组载体
US20030190753A1 (en) Vectors for gene transfer

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20210616

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210616

St.27 status event code: N-4-6-H10-H13-oth-PC1903